Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
holding | CVS | Phantom Stock Credits | 557 | Feb 21, 2022 | Common Stock | 557 | $1.00 | Direct | F2, F3 | |||||
holding | CVS | Stock Option | 27.4K | Feb 21, 2022 | Common Stock | 27.4K | $104.82 | Direct | F4 | |||||
holding | CVS | Stock Option | 32.9K | Feb 21, 2022 | Common Stock | 32.9K | $78.05 | Direct | F5 | |||||
holding | CVS | Stock Option | 22.5K | Feb 21, 2022 | Common Stock | 22.5K | $62.21 | Direct | F6 | |||||
holding | CVS | Stock Option | 70.7K | Feb 21, 2022 | Common Stock | 70.7K | $54.19 | Direct | F7 | |||||
holding | CVS | Stock Option | 141K | Feb 21, 2022 | Common Stock | 141K | $58.34 | Direct | F8, F9 | |||||
holding | CVS | Stock Option | 121K | Feb 21, 2022 | Common Stock | 121K | $74.30 | Direct | F10 |
Id | Content |
---|---|
F1 | Represents shares earned by the reporting person pursuant to certain performance stock units (the "PSUs"), which were granted to the reporting person under the Issuer's 2017 Incentive Compensation Plan on June 5, 2019. The PSUs were earned based on the attainment of certain performance metrics, which performance metrics were certified by the Management and Planning Committee of the Board of Directors of the Issuer on February 21, 2022. |
F2 | Reflects year-end company-match share credits under a non-qualified deferred compensation plan; share credits are payable in cash only, at such time as has been elected by the reporting person. |
F3 | Reflects year-end company-match share credits under a non-qualified deferred compensation plan; share credits are payable in cash only, at such time as has been elected by the reporting person. |
F4 | Option became exercisable in four equal annual installments, commencing 4/1/2017. |
F5 | Option became exercisable in four equal annual installments, commencing 4/3/2018. |
F6 | Option became exercisable in four equal annual installments, commencing 4/1/2019. |
F7 | Option became exercisable in four equal annual installments, commencing 4/1/2020. |
F8 | The number of shares subject to the option were calculated using a 30-day average price. |
F9 | Option became exercisable in four equal annual installments, commencing 4/1/2021. |
F10 | Option becomes exercisable in four equal annual installments, commencing 4/1/2022. |